A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM

Obesity Science & Practice Pub Date : 2025-08-06 eCollection Date: 2025-08-01 DOI:10.1002/osp4.70085

Eion Plenn, Dylan Amin, Jonathan Henry, Gabrielle Leavitt, Jason Walker, Taraneh Soleymani

{"title":"A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.","authors":"Eion Plenn, Dylan Amin, Jonathan Henry, Gabrielle Leavitt, Jason Walker, Taraneh Soleymani","doi":"10.1002/osp4.70085","DOIUrl":null,"url":null,"abstract":"Introduction: Semaglutide 2.4 mg (Wegovy) is the first second-generation anti-obesity medication approved by the FDA for long-term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first-generation anti-obesity medications and amid ongoing national shortages, understanding the real-world experiences of individuals using semaglutide 2.4 mg is crucial. This qualitative study aims to explore the narratives of individuals using semaglutide 2.4 mg for weight management, as expressed in Reddit posts.Methods: One thousand posts from the r/WegovyWeightLoss subreddit between October 10, 2022, and October 6, 2023, were retrospectively analyzed. After excluding irrelevant posts, 660 posts were included in the analysis. A codebook was collaboratively developed and data was coded using qualitative software. Themes were finalized and reviewed.Results: Seven themes were identified from the analysis: medication efficacy (29.4% of coded posts), psychosocial impact of weight loss (22.8%), side effects management (13.3%), barriers to access (10.7%), lifestyle modification (10.2%), support and community (9.2%), and stigma surrounding use of semaglutide 2.4 mg for weight loss (4.4%).Conclusion: This qualitative analysis of Reddit posts provides valuable insights into the real-world experiences of individuals using semaglutide 2.4 mg for weight management. By understanding these user experiences, healthcare providers can better tailor obesity treatment plans and enhance patient-centered care for those using second-generation anti-obesity medications like semaglutide 2.4 mg.","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"11 4","pages":"e70085"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327412/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.70085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Semaglutide 2.4 mg (Wegovy) is the first second-generation anti-obesity medication approved by the FDA for long-term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first-generation anti-obesity medications and amid ongoing national shortages, understanding the real-world experiences of individuals using semaglutide 2.4 mg is crucial. This qualitative study aims to explore the narratives of individuals using semaglutide 2.4 mg for weight management, as expressed in Reddit posts.

Methods: One thousand posts from the r/WegovyWeightLoss subreddit between October 10, 2022, and October 6, 2023, were retrospectively analyzed. After excluding irrelevant posts, 660 posts were included in the analysis. A codebook was collaboratively developed and data was coded using qualitative software. Themes were finalized and reviewed.

Results: Seven themes were identified from the analysis: medication efficacy (29.4% of coded posts), psychosocial impact of weight loss (22.8%), side effects management (13.3%), barriers to access (10.7%), lifestyle modification (10.2%), support and community (9.2%), and stigma surrounding use of semaglutide 2.4 mg for weight loss (4.4%).

Conclusion: This qualitative analysis of Reddit posts provides valuable insights into the real-world experiences of individuals using semaglutide 2.4 mg for weight management. By understanding these user experiences, healthcare providers can better tailor obesity treatment plans and enhance patient-centered care for those using second-generation anti-obesity medications like semaglutide 2.4 mg.

查看原文本刊更多论文

使用2.4 mg西马鲁肽减肥的患者经历的定性分析。

简介：Semaglutide 2.4 mg （Wegovy）是第一个被FDA批准用于长期肥胖治疗的第二代抗肥胖药物。考虑到与第一代抗肥胖药物相比，2.4 mg的semaglutide的有效性，以及在国家持续短缺的情况下，了解使用2.4 mg semaglutide的个人的实际经验至关重要。本定性研究旨在探讨使用2.4 mg西马鲁肽进行体重管理的个体的叙述，正如Reddit帖子所表达的那样。方法：回顾性分析2022年10月10日至2023年10月6日reddit r/WegovyWeightLoss版块上的1000篇帖子。在剔除不相关的帖子后，660个帖子被纳入分析。协作开发了一个代码本，并使用定性软件对数据进行编码。最后确定并审查了主题。结果：从分析中确定了七个主题：药物疗效（占编码帖子的29.4%），减肥的心理社会影响（22.8%），副作用管理（13.3%），获取障碍（10.7%），生活方式改变（10.2%），支持和社区（9.2%），以及使用semaglutide 2.4 mg减肥的耻耻感（4.4%）。结论：对Reddit帖子的定性分析为使用semaglutide 2.4 mg进行体重管理的个人的真实体验提供了有价值的见解。通过了解这些用户体验，医疗保健提供者可以更好地定制肥胖治疗计划，并为使用第二代抗肥胖药物（如semaglutide 2.4 mg）的患者加强以患者为中心的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊